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OBJECTIVE:
 
 To assess the impact of varicose veins (VV)
on generic and disease-specific quality of life (QOL).
METHODS: A cross-sectional analysis performed in a
cohort study based on 166 general practices and 116 spe-
cialist clinics for venous disorders in Belgium, Canada
(Quebec), France and Italy included a sample of 1313 pa-
tients aged 18–75 randomly selected from a registry of
5688 consecutive patients. Generic and disease-specific
QOL was measured by SF-36 and VEINES-QOL. RE-
SULTS: In both genders, age-standardised SF-36 Mental
Component Score (MCS) and Physical Component Score
(PCS) were comparable in patients with VV alone (Men:
PCS 47.6, MCS 46.2; Women: PCS 46.5, MCS 43.9) and
in patients without VV (Men: PCS 45.6, MCS 47.2;
Women: PCS 48.3, MCS 43.0). PCS declined with the se-
verity of signs of venous disorders associated with VV; it
was 42.9 (Men) and 39.4 (Women) in patients with VV
and skin changes, and 37.3 (Men) and 35.5 (Women) in
subjects with VV and ulcer. Similar patterns were found
for VEINES-QOL. In covariance analysis adjusted for co-
morbidity and other determinants of health status, an ad-
justed difference of 0.1 was found for both PCS and
VEINES-QOL scores between patients with VV alone
and patients without VV (P  0.05). Large adjusted dif-
ferences in PCS and VEINES-QOL were observed in pa-
tients with VV and skin changes (differences of 3.0 and
3.1 respectively) and in patients with VV and healed/
open ulceration (5.0 and 3.8 respectively). Compara-
ble results were found when only subjects recruited by
specialists were studied. CONCLUSIONS: In patients
with VV, impairment of quality of life is not associated
with VV themselves but with the severity of concomitant
signs of other venous disorders, such as venous oedema,
skin changes or ulceration. Treatment goals in patients
with VV should clearly distinguish between cosmetic im-
provement and improvement of QOL and symptoms.
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OBJECTIVES: In the PURSUIT trial, eptifibatide was
found to reduce the risk of acute myocardial infarction
(AMI) and mortality (composite) from 15.7% to 14.2%
(relative risk reduction [RRR]  9.5 percent) in patients
presenting with non-ST elevation acute cardiac ischemia
(ACI). A cost-effectiveness analysis, based on the more
favorable United States (US) results of the trial, found
that the cost-effectiveness ratio for eptifibatide for this in-
dication was $16,491 per year of life saved. We sought to
estimate the cost-effectiveness of eptifibatide based on
the results of the entire trial and the expected risk of
AMI/death in a community based sample of patients.
METHODS: Based on logistic regression equations to
predict patient-specific risks of AMI and death using eas-
ily obtainable clinical and electrocardiograph characteris-
tics (and assuming a constant RRR), we estimated the
cost-effectiveness of routine use of eptifibatide in individ-
uals in a population of 2,781 consecutive patients admit-
ted for non-ST elevation ACI. RESULTS: Predictions
were obtained on 2,578 (92.7 percent) of patients who
met inclusion criteria. Of these patients, 1.9 percent died
at 30 days and 12.2 percent had the composite outcome
of AMI or death. Given these overall risks and a constant
RRR, the average cost per year of life saved in our sam-
ple was estimated to be $42,469 per QALY. Moreover,
adjusting each patients risk of AMI and death using indi-
vidual patient characteristics, only 7 percent of patients
were at sufficiently high-risk to warrant therapy under a
threshold of $20,000 per QALY and 42 percent under a
threshold of less than $50,000 per QALY. CONCLU-
SION: Given a constant RRR, use of eptifibatide is eco-
nomically attractive in high-risk patients, but much less
attractive in low risk patients. Strategies to risk stratify
patients to optimize clinical and economic outcomes
should be considered.
